BACKGROUND: Low vitamin D status in pregnancy was proposed as a risk factor of preeclampsia. METHODS: We assessed the effect of vitamin D supplementation (4,400 vs. 400 IU/day), initiated early in pregnancy (10-18 weeks), on the development of preeclampsia. The effects of serum vitamin D (25-hydroxyvitamin D [25OHD]) levels on preeclampsia incidence at trial entry and in the third trimester (32-38 weeks) were studied. We also conducted a nested case-control study of 157 women to investigate peripheral blood vitamin D-associated gene expression profiles at 10 to 18 weeks in 47 participants who developed preeclampsia. RESULTS: Of 881 women randomized, outcome data were available for 816, with 67 (8.2%) developing preeclampsia. There was no significant difference between treatment (N = 408) or control (N = 408) groups in the incidence of preeclampsia (8.08% vs. 8.33%, respectively; relative risk: 0.97; 95% CI, 0.61-1.53). However, in a cohort analysis and after adjustment for confounders, a significant effect of sufficient vitamin D status (25OHD ≥30 ng/ml) was observed in both early and late pregnancy compared with insufficient levels (25OHD <30 ng/ml) (adjusted odds ratio, 0.28; 95% CI, 0.10-0.96). Differential expression of 348 vitamin D-associated genes (158 upregulated) was found in peripheral blood of women who developed preeclampsia (FDR <0.05 in the Vitamin D Antenatal Asthma Reduction Trial [VDAART]; P < 0.05 in a replication cohort). Functional enrichment and network analyses of this vitamin D-associated gene set suggests several highly functional modules related to systematic inflammatory and immune responses, including some nodes with a high degree of connectivity. CONCLUSIONS:Vitamin D supplementation initiated in weeks 10-18 of pregnancy did not reduce preeclampsia incidence in the intention-to-treat paradigm. However, vitamin D levels of 30 ng/ml or higher at trial entry and in late pregnancy were associated with a lower risk of preeclampsia. Differentially expressed vitamin D-associated transcriptomes implicated the emergence of an early pregnancy, distinctive immune response in women who went on to develop preeclampsia. TRIAL REGISTRATION: ClinicalTrials.gov NCT00920621. FUNDING: Quebec Breast Cancer Foundation and Genome Canada Innovation Network. This trial was funded by the National Heart, Lung, and Blood Institute. For details see Acknowledgments.
RCT Entities:
BACKGROUND: Low vitamin D status in pregnancy was proposed as a risk factor of preeclampsia. METHODS: We assessed the effect of vitamin D supplementation (4,400 vs. 400 IU/day), initiated early in pregnancy (10-18 weeks), on the development of preeclampsia. The effects of serum vitamin D (25-hydroxyvitamin D [25OHD]) levels on preeclampsia incidence at trial entry and in the third trimester (32-38 weeks) were studied. We also conducted a nested case-control study of 157 women to investigate peripheral blood vitamin D-associated gene expression profiles at 10 to 18 weeks in 47 participants who developed preeclampsia. RESULTS: Of 881 women randomized, outcome data were available for 816, with 67 (8.2%) developing preeclampsia. There was no significant difference between treatment (N = 408) or control (N = 408) groups in the incidence of preeclampsia (8.08% vs. 8.33%, respectively; relative risk: 0.97; 95% CI, 0.61-1.53). However, in a cohort analysis and after adjustment for confounders, a significant effect of sufficient vitamin D status (25OHD ≥30 ng/ml) was observed in both early and late pregnancy compared with insufficient levels (25OHD <30 ng/ml) (adjusted odds ratio, 0.28; 95% CI, 0.10-0.96). Differential expression of 348 vitamin D-associated genes (158 upregulated) was found in peripheral blood of women who developed preeclampsia (FDR <0.05 in the Vitamin D Antenatal Asthma Reduction Trial [VDAART]; P < 0.05 in a replication cohort). Functional enrichment and network analyses of this vitamin D-associated gene set suggests several highly functional modules related to systematic inflammatory and immune responses, including some nodes with a high degree of connectivity. CONCLUSIONS:Vitamin D supplementation initiated in weeks 10-18 of pregnancy did not reduce preeclampsia incidence in the intention-to-treat paradigm. However, vitamin D levels of 30 ng/ml or higher at trial entry and in late pregnancy were associated with a lower risk of preeclampsia. Differentially expressed vitamin D-associated transcriptomes implicated the emergence of an early pregnancy, distinctive immune response in women who went on to develop preeclampsia. TRIAL REGISTRATION: ClinicalTrials.gov NCT00920621. FUNDING: Quebec Breast Cancer Foundation and Genome Canada Innovation Network. This trial was funded by the National Heart, Lung, and Blood Institute. For details see Acknowledgments.
Authors: A Rajakumar; T Chu; D E Handley; K D Bunce; B Burke; C A Hubel; A Jeyabalan; D G Peters Journal: Placenta Date: 2010-11-13 Impact factor: 3.481
Authors: Kwang-Il Goh; Michael E Cusick; David Valle; Barton Childs; Marc Vidal; Albert-László Barabási Journal: Proc Natl Acad Sci U S A Date: 2007-05-14 Impact factor: 11.205
Authors: Madonna Achkar; Linda Dodds; Yves Giguère; Jean-Claude Forest; B Anthony Armson; Christy Woolcott; Sherry Agellon; Anne Spencer; Hope A Weiler Journal: Am J Obstet Gynecol Date: 2014-11-13 Impact factor: 8.661
Authors: Daniel A Enquobahrie; Michelle A Williams; Chunfang Qiu; David S Siscovick; Tanya K Sorensen Journal: J Matern Fetal Neonatal Med Date: 2011-01-10
Authors: Sunni L Mumford; Rebecca A Garbose; Keewan Kim; Kerri Kissell; Daniel L Kuhr; Ukpebo R Omosigho; Neil J Perkins; Noya Galai; Robert M Silver; Lindsey A Sjaarda; Torie C Plowden; Enrique F Schisterman Journal: Lancet Diabetes Endocrinol Date: 2018-05-31 Impact factor: 32.069
Authors: Carol L Wagner; Bruce W Hollis; Kalliopi Kotsa; Hana Fakhoury; Spyridon N Karras Journal: Rev Endocr Metab Disord Date: 2017-09 Impact factor: 6.514
Authors: Elizabeth V Schulz; Lori Cruze; Wei Wei; John Gehris; Carol L Wagner Journal: J Steroid Biochem Mol Biol Date: 2017-02-13 Impact factor: 4.292
Authors: Mai He; Hooman Mirzakhani; Ling Chen; Robert Wu; Augusto A Litonjua; Leonard Bacharier; Scott T Weiss; D Michael Nelson Journal: Endocrinology Date: 2020-06-01 Impact factor: 4.736
Authors: Kevin Blighe; Bo L Chawes; Rachel S Kelly; Hooman Mirzakhani; Michael McGeachie; Augusto A Litonjua; Scott T Weiss; Jessica A Lasky-Su Journal: Am J Clin Nutr Date: 2017-08-23 Impact factor: 7.045
Authors: Rachel S Kelly; Damien C Croteau-Chonka; Amber Dahlin; Hooman Mirzakhani; Ann C Wu; Emily S Wan; Michael J McGeachie; Weiliang Qiu; Joanne E Sordillo; Amal Al-Garawi; Kathryn J Gray; Thomas F McElrath; Vincent J Carey; Clary B Clish; Augusto A Litonjua; Scott T Weiss; Jessica A Lasky-Su Journal: Metabolomics Date: 2016-12-12 Impact factor: 4.290
Authors: Hooman Mirzakhani; Vincent J Carey; Thomas F McElrath; Nancy Laranjo; George O'Connor; Ronald E Iverson; Aviva Lee-Parritz; Robert C Strunk; Leonard B Bacharier; George A Macones; Robert S Zeiger; Michael Schatz; Bruce W Hollis; Augusto A Litonjua; Scott T Weiss Journal: J Allergy Clin Immunol Pract Date: 2017-09-08
Authors: Allison Ross Eckard; Mary Ann O'Riordan; Julia C Rosebush; Seungeun Thera Lee; Jakob G Habib; Joshua H Ruff; Danielle Labbato; Julie E Daniels; Monika Uribe-Leitz; Vin Tangpricha; Ann Chahroudi; Grace A McComsey Journal: Antivir Ther Date: 2018